Department of Dermatology, François Quesnay Hospital, Mantes-la-Jolie, France.
Dermatology. 2011;223(1):4-8. doi: 10.1159/000329902. Epub 2011 Aug 16.
Temsirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is a new targeted therapy used in advanced renal cell carcinoma and mantle cell lymphoma and is currently tested in several other human tumors. It induces several cutaneous and mucosal side effects, including painful, dose-limiting stomatitis. We report the unusual case of a 77-year-old man who developed severe mucosal, scrotal and perianal cutaneous aphthous-like ulcerations, 6 weeks after introduction of temsirolimus therapy for advanced-stage renal cell carcinoma. Other causes of aphthous-like ulcerations were ruled out. Topical corticosteroids remained ineffective. It led to the interruption of the treatment. Introduction of colchicine resulted in a dramatic improvement within 1 month. Reintroduction of temsirolimus with concomitant colchicine therapy was followed by a delayed recurrence of the lesions. We provide here a review of the potential cutaneous and mucosal side effects of mTOR inhibitors.
替西罗莫司是一种哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂，是一种新的靶向治疗药物，用于治疗晚期肾细胞癌和套细胞淋巴瘤，目前正在对其他几种人类肿瘤进行测试。它会引起多种皮肤和黏膜副作用，包括疼痛、剂量限制的口腔炎。我们报告了一例罕见的病例，一名 77 岁男性在接受替西罗莫司治疗晚期肾细胞癌 6 周后，出现严重的黏膜、阴囊和肛周阿弗他样溃疡。排除了其他导致阿弗他样溃疡的原因。局部皮质类固醇仍然无效。这导致治疗中断。秋水仙碱的引入在 1 个月内显著改善。重新开始替西罗莫司治疗并同时使用秋水仙碱治疗后，病变延迟复发。我们在此回顾了 mTOR 抑制剂潜在的皮肤和黏膜副作用。
